Add to ORKGThe cost of developing new drugs has increased by ~100 fold in recent decades, largely due to high attrition rate in clinical development caused by cardiotoxicity. Since the recent discovery of human induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs), it has been developed as a novel, promising in vitro research tool in preclinical testing of drug-induced cardiotoxicity. However, major limitation of currently available hiPSC-CMs is their immature phenotype, which can hinder evaluation of contractile dysfunction. Existing contractility monitoring on hiPSC-CMs is currently being done at low throughput or by using surrogate markers (e.g. impedance). In addition, there has been no detailed cross-site validation study to evaluat...
Contractility of the myocardium engines the pumping function of the heart and is enabled by the coll...
The majority of data available for drug predictive safety and disease/polymorphism modelling are bas...
With highly regulated safety requirements, the average cost of drug development is $2.5B, which has ...
The cost of developing new drugs has increased by ~100 fold in recent decades, largely due to high a...
The development and screening of new chemical entities is often a lengthy and costly process, which ...
Animal models are 78% accurate in determining whether drugs will alter contractility of the human he...
The development and screening of new chemical entities is often a lengthy and costly process, which ...
The majority of data available for drug predictive safety and disease/polymorphism modelling are bas...
Animal models are 78% accurate in determining whether drugs will alter contractility of the human he...
In recent decades, drug development costs have increased by approximately a hundredfold, and yet abo...
In recent decades, drug development costs have increased by approximately a hundredfold, and yet abo...
The global cost of heart failure is USD$45 billion and set to double in the next 15 years. The only ...
Introduction: Human induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) preparations are ...
In drug development it is important to assess potential cardiotoxicity of drug candidates as early i...
With highly regulated safety requirements, the average cost of drug development is $2.5B, which has ...
Contractility of the myocardium engines the pumping function of the heart and is enabled by the coll...
The majority of data available for drug predictive safety and disease/polymorphism modelling are bas...
With highly regulated safety requirements, the average cost of drug development is $2.5B, which has ...
The cost of developing new drugs has increased by ~100 fold in recent decades, largely due to high a...
The development and screening of new chemical entities is often a lengthy and costly process, which ...
Animal models are 78% accurate in determining whether drugs will alter contractility of the human he...
The development and screening of new chemical entities is often a lengthy and costly process, which ...
The majority of data available for drug predictive safety and disease/polymorphism modelling are bas...
Animal models are 78% accurate in determining whether drugs will alter contractility of the human he...
In recent decades, drug development costs have increased by approximately a hundredfold, and yet abo...
In recent decades, drug development costs have increased by approximately a hundredfold, and yet abo...
The global cost of heart failure is USD$45 billion and set to double in the next 15 years. The only ...
Introduction: Human induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) preparations are ...
In drug development it is important to assess potential cardiotoxicity of drug candidates as early i...
With highly regulated safety requirements, the average cost of drug development is $2.5B, which has ...
Contractility of the myocardium engines the pumping function of the heart and is enabled by the coll...
The majority of data available for drug predictive safety and disease/polymorphism modelling are bas...
With highly regulated safety requirements, the average cost of drug development is $2.5B, which has ...